Why did Cigna (CI) stock move recently?

On 7/28/2026, Cigna moved +3.4% — Cigna shares rose with the broader market and managed care sector ahead of its Q2 2026 earnings report on July 30; no company-specific catalyst was reported today. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Cigna (CI) overvalued or fairly valued?

MarketChacha shows Cigna's valuation in context — a trailing P/E of about 12.0, a forward P/E of about 9.1, a price-to-book of about 1.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Cigna's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (2.18×) from reported figures — education, not a rating.

What is Cigna's revenue?

Cigna reported revenue of $274.9B for FY2025, with net profit of $6.0B, per official filings.

What is the share price of Cigna (CI)?

Cigna last traded at $304.11 (+1.9% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Cigna

CI · NYSE · Healthcare · United States

Snapshot

TickerCI

ExchangeNYSE

SectorHealthcare

IndustryHealthcare Plans

CountryUnited States

Employees65,669

HeadquartersBloomfield, United States

Websitewww.thecignagroup.com

Filings tracked19

About Cigna

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

Who owns it

Insiders1.4%
Institutions92.2%
Public & other6.3%

2,227 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.87%
Vanguard Capital Management LLC6.54%
State Street Corporation4.80%
Dodge & Cox Inc.4.61%
Massachusetts Financial Services Co.3.95%
Sanders Capital, LLC3.84%
FMR, LLC3.03%
Geode Capital Management, LLC2.37%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion2.18×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend2.6% → 2.2%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 19% · PAT 7%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $74.6B · EPS 7.42

Est. earnings growth -8.1%

Next fiscal year

Rev $299.2B · EPS 33.48

Est. earnings growth +9.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$274.9B

Net margin

2.2%

ROE

14.3%

Revenue CAGR (2y)

+18.7%

Profit CAGR (2y)

+7.4%

EPS (FY2025)

22.18

Net profit (FY2025)

$6.0B

Ask MarketChacha about CI

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 28, 2026
Cigna shares rose with the broader market and managed care sector ahead of its Q2 2026 earnings report on July 30; no company-specific catalyst was reported today.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about CI

Why did CVS Health drop ~6% after a big Q2 beat AND raised guidance?c/usmarkets · 8/5/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$274.9B	$6.0B	22.18	2.2%	14.3%
FY2024	$247.1B	$3.4B	12.12	1.4%	8.4%
FY2023	$195.3B	$5.2B	17.39	2.6%	11.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$71.7B	$1.7B	6.29	2.3%
2026Q1	$68.5B	$1.7B	6.26	2.4%
2025Q3	$69.7B	$2.0B	6.98	2.8%
2025Q2	$67.2B	$1.5B	5.71	2.3%
2025Q1	$65.5B	$1.3B	4.85	2.0%
2024Q3	$63.7B	$825.0M	2.63	1.3%
2024Q2	$60.5B	$1.6B	5.45	2.7%
2024Q1	$57.3B	$-212.0M	-0.97	-0.4%
2023Q3	$49.0B	$1.4B	4.74	3.0%
2023Q2	$48.6B	$1.5B	4.92	3.1%
2023Q1	$46.5B	$1.3B	4.24	2.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/30/2026
8-K — Results of operations, Exhibits
SEC7/30/2026material
8-K — Reg FD disclosure
SEC5/13/2026material
8-K — Results of operations, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026
8-K — Shareholder vote results
SEC4/27/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC3/3/2026material
8-K — Reg FD disclosure
SEC2/27/2026material
10-K filing
SEC2/26/2026
8-K — Results of operations, Exhibits
SEC2/5/2026material

2025

8-K — Other events
SEC11/18/2025material
8-K — Results of operations, Exhibits
SEC10/30/2025material
10-Q filing
SEC10/30/2025
8-K — Executive/director change
SEC10/20/2025material
8-K — Material agreement, Material financial obligation, Other events, Exhibits
SEC9/4/2025material
8-K — Reg FD disclosure
SEC9/2/2025material
8-K — Results of operations, Exhibits
SEC7/31/2025material
10-Q filing
SEC7/31/2025
8-K/A — Executive/director change
SEC7/28/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.